

Klerksdorp CRS

Rustenburg CRS

Tembisa CRS

Pretoria CRS

III Testings

Filt Testings

Established to conduct HIV Vaccine Trials

2005

40 trials >7,500 screened >3,000 enrolled

Established to conduct HIV Epidemiology Studies to prepare for HIV Vaccine Trials

2008

38 trials >10,500 screened >4,500 enrolled

Established to conduct TB Treatment Trials

2008

29 trials >4,000 screened >2,300 enrolled Acquired to conduct Pharma & PK Trials

2020

76 trials ≥700 screened ≥ 500 enrolled

Conducted >180 trials and research studies in the past 16 years focusing on:

- HIV vaccines & prevention (oral, topical, and long-acting injectable PrEP)
- TB treatment, Host-directed therapy, TB vaccines & TB preventative therapy
- COVID-19 vaccines, -COVID-19 mAb & COVID-19 treatment
- Diagnostics and socio-behavioral studies.

Enrolled >59 500 participants in trials and research studies (Clinical Research Division)

- 23 500 Thibela TB (enrollment at mine shafts)
- 25 552 Sisonke vaccine roll-out to Healthcare Workers (enrollment at Department of Health Vaccination Sites)
- 10 500 enrolled in remaining trials and research studies (enrollment at 4 Clinical Research Sites)

Aurum's distinct strengths:

- CRS pluripotency
- Collective scientific, operational & management experience of its research leadership
- High-functioning resources & systems to effectively implement large-scale complex clinical trials (both network & Investigator-lead).

Each CRS brings a unique complement of skills, populations, facilities, and experience

PROGRAMMATIC AREAS



COVID-19



TB Treatment



TB Vaccines



HIV Treatment and PrEP




HIV Vaccines




Special Projects








HIV PREVENTION, STIS & CONTRACEPTION





We have seen the impact of clinical trials saving millions of lives in the COVID-19 pandemic and we are now even more committed to continue our search for safer, more effective tools to address the continuing TB and HIV pandemics!

FIND US ONLINE





